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Cancer is often associated with multiple and progressive genetic alterations in genes that are important for normal
development. BCAS3 (Breast Cancer Amplified Sequence 3) is a gene of unknown function on human chromosome 17q23,
a region associated with breakpoints of several neoplasms. The normal expression pattern of BCAS3 has not been studied,
though it is implicated in breast cancer progression. Rudhira, a murine WD40 domain protein that is 98% identical to BCAS3 is
expressed in embryonic stem (ES) cells, erythropoiesis and angiogenesis. This suggests that BCAS3 expression also may not be
restricted to mammary tissue and may have important roles in other normal as well as malignant tissues. We show that BCAS3
is also expressed in human ES cells and during their differentiation into blood vascular precursors. We find that BCAS3 is
aberrantly expressed in malignant human brain lesions. In glioblastoma, hemangiopericytoma and brain abscess we note high
levels of BCAS3 expression in tumor cells and some blood vessels. BCAS3 may be associated with multiple cancerous and
rapidly proliferating cells and hence the expression, function and regulation of this gene merits further investigation. We
suggest that BCAS3 is mis-expressed in brain tumors and could serve as a human ES cell and tumor marker.
Citation: Siva K, Venu P, Mahadevan A, Shankar SK, Inamdar MS (2007) Human BCAS3 Expression in Embryonic Stem Cells and Vascular Precursors
Suggests a Role in Human Embryogenesis and Tumor Angiogenesis. PLoS ONE 2(11): e1202. doi:10.1371/journal.pone.0001202
INTRODUCTION
Development of multicellular organisms requires controlled and co-
ordinated tissue growth. Misregulation of molecular pathways that
control normal embryo or tissue development can result in aberrant
growth and can lead to cancer [1]. Not surprisingly, several
developmentally important molecules are key mediators of the
cancer phenotype when aberrantly expressed [2,3]. Multiple and
progressive genetic changes accompanied by chromosomal aberra-
tionsareoftentheunderlying cause [4].Human chromosome17has
been well studied in this regard. Its complex rearrangement and
duplication structure predispose it to non-allelic homologous
recombinations that cause several micro-deletion disorders [5,6].
Cruciform structures formed by direct and inverted repeats make it
susceptible to one of the most common somatic rearrangement
events characterized, isodicentric 17q, which is associated with
several cancers and signifies poor prognosis [7]. 17q23 amplification
occurs in about 20% of primary breast tumors [8–12]. Gain of
chromosome arm 17q is the most frequent chromosomal change in
neuroblastoma [13] suggesting that this region includes genes critical
fortumorigenesis.Anincreaseddosageofgenes onchromosome17q
are likely to provide selective growth advantage to human ES cells
for maintenance in vitro as human ES cells in culture show distinctive
chromosomal abnormalities involving this region [14]. A compar-
ative genomic hybridization analysis of medulloblastomas identified
chromosomal imbalances with high-level amplifications involving
17q22-q24 and subsequent candidate gene analyses revealed
amplification of RPS6KB1, APPBP2, PPM1D and BCAS3 [15].
BCAS3 is a large gene located at 17q23 and encodes a predicted
conserved WD40 domain protein 98% identical to murine
Rudhira [16]. We have shown earlier that Rudhira is a cytoplasmic
protein expressed at high levels in ES cells, blood islands and the
erythroid lineage during embryonic development [16]. In both the
embryo and the adult Rudhira expression is seen in angiogenic
precursors. The spatio-temporal expression pattern of Rudhira is
well characterized but its function is not known. The develop-
mental expression of BCAS3, the human ortholog of rudhira is not
reported. However BCAS3 is amplified in 9% of primary breast
tumors [17], is expressed in tumor-derived cell lines like HeLa and
MCF-7 and is implicated in breast cancer progression [16,18].
Given this result and the observation that many aberrations of
chromosome 17 map to the region of BCAS3, we analyzed its
expression during normal development and in tumors. We used
human ES cells and differentiating embryoid bodies as models of
early human embryonic development and report BCAS3 expression
in undifferentiated ES cells and in vascular precursors. We also show
that BCAS3 is mis-expressed in different types of brain lesions that
include a malignant glial tumor, a highly mitotic vascular tumor
arising from meninges (hemangiopericytoma) and the newly formed
channels in the wall of brain abcess. Our results suggest new roles for
BCAS3 in human blood vascular development, an integral part of
tumorigenesis and repair mechanism.
RESULTS
Expression of BCAS3 in human ES cells and vascular
precursors
As the developmental expression of human BCAS3 has not been
reported due to obvious technical and ethical reasons, we began
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cells in culture affords a more tractable model for early human
development. We found expression of BCAS3 in the cytoplasm of
undifferentiated ES cells (Fig. 1 A–D). Flow cytometry analysis
showed that more than 90% of undifferentiated ES cells express
BCAS3 (Fig. 1I).
Having established BCAS3 expression in pluripotent cells, we
examined its expression in blood vessel precursors as is observed in
the case of mouse rudhira. Human ES cells can also spontaneously
differentiate into blood islands which are precursors to embryonic
blood vessels. This process is less efficient than in mouse ES cells
and is often carried out under influence of growth factors. We
allowed human ES cells to differentiate spontaneously into
embryoid bodies (EB) that contain blood islands and nascent
blood vessels. Earlier studies indicate that the maximal expression
of vascular markers in human EBs is detected between week 1 and
2 of differentiation [19]. Hence we fixed EBs at 8, 10 and 14 days
of differentiation and analyzed for expression of BCAS3 and cell
surface markers for the blood vascular lineage.
VEGFRII expression indicates the presence of early vascular
precursors such as hemangioblasts [20]. Both VEGFRII and
Platelet Endothelial Cell Adhesion Molecule (PECAM) are
expressed in blood islands which have endothelial and hemato-
poietic precursors. Differentiated endothelial cells also express the
adhesion molecule ICAM2 [21,22]. We examined BCAS3
expression in differentiating EBS and simultaneously stained the
cultures with VEGFRII or PECAM or ICAM2 to check for any
co-localization with BCAS3. At day 8 of differentiation BCAS3
was detected in small clusters near the periphery of the EB.
Staining for vimentin indicated that these were cells of
mesodermal origin (Fig. 2 A–D). To examine whether these
clusters were vascular precursors we double stained for VEGFRII.
Expression of BCAS3 overlapped with VEGFRII in cell clusters
resembling blood islands (Fig. 2 E–H) as well as in nascent vessels
(fig. 2 I–L). Expression of BCAS3 was not uniform with some cells
expressing higher BCAS3 level (Fig. 2E, H arrow). VEGFRII was
also detected at day 10 in larger clusters which also expressed
BCAS3 (Figure 3 A–D). BCAS3 expression was seen in day 10 EBs
in clusters of cells expressing PECAM (Fig. 3 E–H). At day 14
BCAS3 expression was seen in few PECAM-expressing cells (Fig. 4
A–D) as well as in clusters of ICAM2-expressing cells (Fig. 4 E–L).
On closer examination at higher magnification by confocal
microscopy we found that BCAS3 and ICAM2 were not co-
expressed in the same cell (Fig. 4 I–L). ICAM-2 is also a marker of
differentiated endothelial cells of nascent vessels. We saw
expression of BCAS3 in a few vessels that were also expressing
ICAM2. However cells co-expressing BCAS3 and ICAM2 were
rarely seen (Fig. 4 M–P). Immunostaining for BCAS3 with the
antibody was compared to control antibody staining at all stages
analyzed (Fig. 2 M–P, 3Q-T and data not shown).
BCAS3 mRNA but not protein is expressed in the
normal brain and in glioma cell lines
While Rudhira protein is not detected in mouse adult tissues,
rudhira RNA can be detected in various adult tissues by RT-PCR.
In particular, multiple splice variants are seen in the mouse brain
[16]. To test whether this is so in human, we analyzed normal
adult brain cDNA by PCR. BCAS3 amplicon was seen in cDNAs
from all regions of the brain (Fig. 5A). We also amplified BCAS3
from cDNA of various glioma cell lines that represent malignant
human brain tumor cells (Fig. 5B). We then examined frozen
sections of human frontal cerebral cortex for BCAS3 protein
expression by immunofluorescence staining. Details of samples
analyzed are listed in Table 1. BCAS3 was absent from control
normal (non-malignant) brain samples (Fig. 6). This is in
agreement with the observation that Rudhira protein is not
detected in mouse brain.
BCAS3 is expressed in human brain tumors of
different cell lineage and inflammatory brain
abscess
Having established the expression of BCAS3 in glioma cell lines in
vitro, we looked for similar expression in brain tumor tissue and
wall of brain abscess rich in vasculature (Table 1). We found a large
number of BCAS3- expressing cells in different types of brain
lesions including glioblastoma, hemangiopericytoma and wall of
an abscess. Eight samples showed strong immunoreactivity for
BCAS3; over 50% of the cells being BCAS3
+ (five glioblastomas,
Figure 1. BCAS3 expression in human ES cells. Human ES cell cultures stained with (A) anti-BCAS3 antibody or (E) isotype control antibody and co-
immunostained with (B, F) SSEA4. (C, G) show nuclei stained with DAPI. (D, H) are merged images of all three respective panels on their left. Arrows
indicate nuclei of some feeder layer fibroblasts. (I) Flow cytometry analysis of human ES cells expressing Rudhira. Graphs show counts for Isotype
control (shaded) and Rudhira positive (unshaded) cells. Scale bar: 50 mm.
doi:10.1371/journal.pone.0001202.g001
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cases, BCAS3 localized to the cytoplasm (Fig. 7). Negative controls
in which primary antibodies were omitted did not show any
specific immunostaining. The expression of BCAS3 in the cells
was rather random and showed a distinct association to vascular
component of neoplasms of various cell lineages and inflammatory
lesions. The labeling was noted along the endothelial aspect and
the adjacent pericytes of small arterioles and endothelium of some
of the larger blood vessels but not the smooth muscle cells.
Labeling was seen in vascular sprouts in the wall of the brain
abcess (one case) (Fig. 7A), the newly formed vessels in five cases of
glioblastoma multiforme (high-grade astrocytic tumor) (Fig. 7B, D,
Figure 2. Expression of BCAS3 in embryoid bodies at day 8 of differentiation. Human EBs at day 8 of differentiation immunostained for (A, E, I)
BCAS3 (green), (M) isotype control (green), (B) Vimentin (red) and (F, J, N) VEGFRII (red). (C, G, K, O) show nuclei stained with DAPI. (D, H, L, P) are
merged images of respective panels to their left. Arrowheads indicate groups of cells expressing BCAS3. Arrows indicate (E–H) blood islands or (I–L)
nascent vessels. Scale bar: 50 mm.
doi:10.1371/journal.pone.0001202.g002
Figure 3. Expression of BCAS3 in embryoid bodies at day 10 of differentiation. Human EBs at day 10 of differentiation immunostained for (A, E)
BCAS3 (green), (B) VEGFRII (red) and (F) PECAM (red). (C, G) show nuclei stained with DAPI. (D, H) are merged images of respective panels to their left.
Scale bar: 50 mm.
doi:10.1371/journal.pone.0001202.g003
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PLoS ONE | www.plosone.org 3 November 2007 | Issue 11 | e1202Figure 4. Expression of BCAS3 in embryoid bodies at day 14 of differentiation. Human EBs at day 14 of differentiation immunostained for (A, E, I,
M) BCAS3 (green), (Q) isotype control (green), (B) PECAM (red) and (F, J, N, R) ICAM2 (red). (C, G, K, O, S) show nuclei stained with DAPI. (D, H, L, P, T)
are merged images of respective panels to their left. Boxed area in (E–H) imaged at higher magnification shown in (I–L) respectively. Scale bar: (A, M,
Q) 50 mm (E, I) 100 mm.
doi:10.1371/journal.pone.0001202.g004
Figure 5. BCAS3 RNA expression in human brain and glioma cell
lines. PCR analysis of cDNA from normal brain (A) and glioma cell lines
(B) using BCAS3- specific primers. M: marker, WB: whole brain, CB:
cerebellum, CC: Cerebral cortex, HC: hippocampus. U87MG, U373MG,
LN18, LN229: glioma cell lines.
doi:10.1371/journal.pone.0001202.g005
Figure 6. BCAS3 is not expressed in normal human frontal cerebral
cortex (from two individuals). Panels to the extreme left in A and B
show immunostaining on frozen sections of brain samples with anti-
BCAS3 antibody, panels in the middle are DIC (differential interference
contrast) images of the same sections and panels on the extreme right
show adjacent sections stained with hematoxylin-eosin. Scale bar:
50 mm.
doi:10.1371/journal.pone.0001202.g006
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tumor of meningio-vascular origin) (Fig. 7C, E). In addition, the
undifferentiated glial tumor cells in glioblastoma multiforme
(grade IV) also revealed cytoplasmic labeling. The cells in most
low-grade glial tumors of different cell lineages (grade I–III) failed
to show expression of BCAS3 protein. BCAS3 positive cells in the
tumors co-expressed GFAP (Glial Fibrillar Acidic Protein),
a marker of the glial cells (Fig. 8).
Table 1. Details of the samples used for the study.
..................................................................................................................................................
Sample number Tumor type Grade (WHO Grade) Age/Sex Expression status of BCAS3
T37 Normal–Cerebral cortex - 4/M -
T38 Normal–Cerebral cortex - 11/M -
T39 Normal–Cerebral cortex - 22/F -
T54 Normal–Cerebral cortex - 29/M -
T63 Normal–Cerebral cortex - 19/F -
T76 Normal–Cerebral cortex - 16/M -
T86 Normal–Cerebral cortex - 19/M -
T89 Normal–Cerebral cortex - 42/M -
T65 Brain Abscess (organized wall) - 67/M -
T66 Brain Abscess (vascular) - 50/F +
T1350 Brain Abscess (low vascularity) - 60/M -
T1441 Histiocytosis (low vascularity) - 16/M -
T57 Atrial myxoma of heart (avascular) - 45/M -
T61 Atrial myxoma of heart (avascular) - 38/F -
T1345 Meningioma meningothelial I 59/M -
T62 Fibroblastic Meningioma I 48/F -
T67 Meningioma meningothelial I 50/F -
T1443 Meningioma meningothelial I 35/F -
T52 Atypical Meningioma II 57/M -
T56 Atypical Meningioma II 48/F -
T1640 Hemangiopericytoma II 20/M +
T72 Hemangiopericytoma (with high mitosis) III 35/F +
T1852 Schwannoma I 35/M -
T2013 Schwannoma I 29/F -
T1433 Paraganglioma I 45/M -
T1637 Plexiform neurofibroma I 25/M -
T77 Choroid plexus papilloma I 22/F -
T69 Pilocytic astrocytoma I 33/M -
T64 Fibrillar astrocytoma II 6/M -
T1628 Anaplastic astrocytoma III 18/M -
T70 Anaplastic astrocytoma III 7/F -
T59 Oligodendroglioma II 13/M -
T68 Oligodendroglioma II 45/F -
T2017 Ependyoma III 73/F -
T53 Oligoastrocytoma III 48/M -
T60 Anaplastic Oligodendroglioma III 27/M -
T74 Anaplastic Oligodendroglioma III 37/F -
T71 Glioblastoma multiforme IV 42/F +
T1850 Glioblastoma multiforme IV 45/F +
T1866 Glioblastoma multiforme IV 65/M +
T1901 Glioblastoma multiforme IV 53/F +
T1349 Glioblastoma multiforme IV 42/F +
T75 Glioblastoma (large necrotic zones) IV 13/F -
T73 Glioblastoma (infilterating front) IV 45/M -
T1439 Medulloblastoma (low vascularity) IV 9/M -
doi:10.1371/journal.pone.0001202.t001
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Several cancers result from the mis-regulated expression of
developmentally important genes. While there is obvious benefit
in studying human tumor biology and tumor progression,
elucidating gene function is often hindered by the lack of a suitable
model to study the developmental and pathogenetic role of the
tumor-associated genes. In this regard animal models of cancer
have been extremely valuable in elucidating molecular pathways
and mechanisms of disease progression. However several differ-
ences are seen in development and stem cell differentiation in
humans compared to that in animal models and their cultured
derivatives. Till recently, studies on developmental and patholog-
ical human gene expression have been restricted to tissues from
fixed aborted fetuses, or cell- and tissue- cultures derived from
them. The advent of human ES cell technology has opened up
new avenues of investigation and now allows one to address
developmental roles of human disease genes. We have taken
advantage of this system to analyze the developmental and
pathological expression of BCAS3 a gene known to be important
in breast cancer. Our analysis suggests new conserved roles for
BCAS3 in tumor manifestation and progression and in tissue
healing.
Figure 7. BCAS3 expression in human brain lesions. (A–H) Cryosections immunostained for BCAS3 (green). Fluorescent image with DAPI (blue)
marking the nucleus or DIC image of the same field is shown as indicated. Panels to the far right show adjacent sections stained with hematoxylin-
eosin. BCAS3 positive tumor cells are indicated by arrows and vessel cells by arrowheads. (I) Graph showing percent BCAS3-expressing cells in normal
brain and tumor samples. Sample numbers indicated on X axis are described in Table 1.
doi:10.1371/journal.pone.0001202.g007
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gene
Expression of BCAS3 mRNA in medulloblastoma of cerebellum and
BCAS3 protein in breast cancer has been reported [15,18]. Such an
expression profile suggests that BCAS3 expression is not restricted to
a specific tissue. The function of BCAS3 is not known either in
embryogenesis or during tumor progression. Our study suggests that
BCAS3 may have a role during embryogenesis and in tumorigenesis
like many other genes that were discovered for their oncogenic role
and found tobekeyplayersinembryogenesis.For example,Smad4/
Dpc4, a signaling molecule of TGF-b- related pathways required for
gastrulation and anterior development of the mouse embryo is
involved in 50% of pancreatic cancers [23]. Similarly expression of
BRCA-1, an infamous breast cancer gene, is associated with
embryonic cellular proliferation and with differentiation of ectoder-
mally- and mesodermally- derived tissues in the mouse [24,25].
BCAS3 is expressed in developmental and
pathological angiogenesis
The kinetics of vascular marker gene expression during mouse EB
differentiation is well documented and allows the detection of
successive maturation steps [20]. Similar analysis done on human
EBs showed that the early vascular markers VEGFRII and
PECAM/CD31 appeared by the first week of differentiation [19].
The majority of early vascular markers peak between week 1 and 2
of differentiation. Hence we restricted our analysis till day 14 of
differentiation. We observe that like in mouse EBs, human EBs also
express BCAS3 in early stages of vascular development as indicated
by VEGFRII and PECAM expression. BCAS3 expression at later
stages in seen only in a few differentiated ICAM2+ endothelial cells
indicating that BCAS3 expression in the vasculature is down-
regulated in later stages of vascular development. As seen for
Rudhira in mouse EBs and mouse tissues [16] cells that co-express
BCAS3 and ICAM2 are rarely detected. This suggests that the
sequence of vascular gene expression in human EBs parallels that in
mouse EBs. As in mouse vascular development Rudhira/BCAS3 is
expressed transientlyindifferentiated human endothelialcells during
human vascular development. This suggests an important role for
BCAS3 in human angiogenesis.
BCAS3 RNA is expressed in the normal human brain and also in
glial celllines.In caseof thenormal brain,the cDNArepresentedthe
entire tissue including the blood vessels. Hence, the amplicon may
represent RNA from the few blood vessels that express BCAS3 as
seen in mouse embryos and models of angiogenesis. Rudhira is also
expressed during normal physiological angiogenesis though it is not
detected in differentiated endothelium. Greater the neo-vascularisa-
tion in tumors, greater is their chance of metastatic spread. As
BCAS3 expression is associated with vascular precursors derived
from human ES cells, it is possible that BCAS3 plays a role in the
formation of tumor vessels.
We report that the protein encoded by BCAS3 is mis-expressed
in brain neo plastic and reparative lesions like glioma, abscess and
hemangiopericytoma. The vessels in an abscess express enhanced
levels of adhesion molecules like ICAM-1 (intercellular cell
adhesion molecule) and PECAM (platelet endothelial cell adhesion
molecule) which are not expressed in the normal brain and are
thought to be involved in guiding the immune cells to the abscess
[26]. BCAS3 is not detected in low grade tumors indicating
a temporal and spatial association of BCAS3 to highly mitotic
undifferentiated tumor cells and neo-angiogenesis. Similarly, many
of the vascular sprouts in the wall of an abcess also showed
constitutive expression, reflecting that the angiogenesis in the wall
of inflammatory lesion is essentially similar to tumor blood vessels,
ontologically. The vascular component- either arterioles or
capillaries- in normal cerebral cortex did not show expression of
BCAS3 indicating the blood vessels in normal brain are quiescent,
of low turn over and the biology is distinct from vessels in tumors
or active inflammatory lesions.
Blood vessels are composed of two interacting cell types.
Endothelial cells form the inner lining of the vessel wall and
perivascular cells referred to as pericytes, vascular smooth muscle
cells (SMCs) or mural cells. Depending on their location during
Figure 8. BCAS3 is expressed in glial cells in glioblastoma multiforme. Human glioblastoma sections immunostained for (A) BCAS3 (green) and (B)
anti-GFAP (red). DAPI (blue) marks the nucleus. Arrows indicate glial tumor cells expressing BCAS3 (A) or GFAP (B).
doi:10.1371/journal.pone.0001202.g008
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mesenchymal cells [27,28]. Vessels associated with tumors have
abnormal wall structure and branching patterns. These perivas-
cular cells are loosely associated with the endothelium [29]. A
tumor arising from these pericytes could be arising from
progenitor mesenchymal cells, thus expressing BCAS3.
BCAS3 could serve as a marker of tumor progression
BCAS3 is expressed in the neo-angiogenic component of
glioblastoma, hemangiopericytoma and brain abcess wall. In
addition, its expression is noted in some of the neoplastic cells of
glial lineage (grade IV). Cell lines are a more homogenous
population and BCAS3 expression in glioma lines is suggestive of
expression in non-vascular neuroectodermal cells. This suggests
that the expression of BCAS3 RNA and constitutive presence in the
tumor cells and newly formed blood vessels but not in the capillary
endothelium of the normal brain is related either to the
proliferative nature or an event associated with the undifferenti-
ated and multipotent nature of the cells. The gene controlling this
is probably turned off with maturation. In view of this, BCAS3
could be a surrogate marker for angiogenesis in a reparative
healing process or tumor progression to higher grade of
malignancy, a common phenomenon in cell biology.
BCAS3 is located in a chromosomal region that carries several
oncogenes. It is a target gene of metastasis-associated protein1
(MTA1) [18]. MTA1 is a component of the nucleosome remodeling
and deacetylating (NURD) complex that contains both histone
deacetylase and nucleosome remodeling activity. By expression
profiling,MTA1wasidentifiedasatargetofthec-MYConcoprotein
in primary human cells and has been implicated in cellular
transformation through its ability to regulate the epithelial to
mesenchymal transition and metastasis [30]. MTA1 binds to
estrogen response elements (ERE) on the enhancer 12 kbp
downstream of the transcription start site of BCAS3. Breast cancer
patients with high BCAS3 expression and ER/PR positive
expression show impaired response to tamoxifen [31]. Hence,
a study of the expression of BCAS3 can help in assessing prognosis.
We also find that most samples expressing BCAS3 are grade III
and IV brain tumors though not all high-grade samples showed
expression. This reflects the heterogeneity in the neoplastic cell
population of brain tumors and a probable role of BCAS3 in
tumor progression as seen in the breast tumors [18].
Whether expression of BCAS3 is a cause or an effect of the
general transformation and metastasis of tumors requires further
studies. This is the first report on BCAS3 expression during
development and in brain malignancies. The expression profile
suggests that BCAS3 may play a role during both embryogenesis
and tumorigenesis. An in- depth study of BCAS3 regulation and its
role in progression of tumors of different organs may reveal
correlation with prognosis and disease recurrence.
MATERIALS AND METHODS
Culture and differentiation of Human ES cells
Human ES cells (HUES9) [32] (hES facility, Harvard University,
Cambridge, MA, http://mcb.harvard.edu/melton/hues) were
grown on irradiated mouse embryonic fibroblasts (MEFs) in
medium containing 80% DMEM, 20% knockout serum, 2 mM L-
glutamine, 0.1 mM b-mercaptoethanol, 1% non-essential amino
acids and 4 ng/ml basic fibroblast growth factor (bFGF). For
differentiation, the colonies were cut and maintained in the EB
medium on bacteriological dishes without feeders. EB medium is
similar to ES cell medium except the following: it is without bFGF,
knockout serum is replaced by fetal calf serum, and glutamine is
4 mM. The floating EBs were allowed to attach on tissue culture
dishes and fixed at different days post-attachment.
Culture of glioma cells lines
U87MG, U373MG, LN18 and LN229 -glioma cell lines (Kind gift
from M.R.S. Rao, JNCASR) were grown in DMEM containing
10% serum and 2 mM L-glutamine. Cells were scraped out of the
culture dish and RNA was isolated.
Human brain cDNAs
Marathon-Ready human brain cDNAs were obtained from
Clontech (kind gift from A. Anand, JNCASR).
Clinical material–collection and processing
Forty-six surgically resected formalin-fixed pathological tissue
samples were obtained from the archives of human brain tissue
repository (Human Brain Bank–a National Research facility,
Department of Neuropathology, National Institute of Mental
Health and Neurosciences (NIMHANS), Bangalore, India). The
brains have been collected with informed consent from the close
relatives after the death of the patients. This is in line with legally
and ethically approved practice in India. The consent form has
been approved by Institutional Scientific Ethics Committee-
NIMHANS for the use of Human Biological Material for
Scientific Research and Archiving.
The samples were subsequently cryopreserved in 30% sucrose
solution. Cryosections 10 mm thick were picked on gelatin- coated
slides for immunostaining and stored at 270uC. The age of the
patients ranged between 4 years and 65 years (M:F=25:21).
Relatively normal control samples for comparison were cerebral
cortical tissue resected during epilepsy surgery, which were free of
pathology on detailed histological evaluation and were obtained
with informed consent. The consent forms and the biological
samples for research have been approved by Institutional Scientific
Ethics Committee for the use of Human Biological Material for
Scientific Research and Archiving- NIMHANS, Bangalore, India.
The samples have been coded to maintain the confidentiality of
the patients. The sample numbers used in the manuscript are
coded and the original data is not accessible to the investigating
scientist, the number indicated is used only for the purpose of this
study and it cannot be tied to any other information to trace the
individual. Thus the strict confidentiality is preserved as per the
policy of the Human Brain Bank, NIMHANS, Bangalore. The
histological diagnosis of the tissues examined is indicated in the
Table 1. The brain tumors were reviewed and graded according to
WHO classification for degree of malignancy.
Reverse Transcription–Polymerase Chain Reaction
(RT-PCR)
2 mg total RNA from cultured glioma cell lines was reverse
transcribed using Superscript II (GIBCO) and random primers,
according to the manufacturer’s instructions. PCR was performed
using the following BCAS3-specific primers: 466-1F 59 GAATTC-
CATGGAGAGCGTCGTGACTTTTCTG 39; 466-1R 59
GAGCTCGAGGGACTGGTGACAGCGAATCAGC 39
Immunostaining and imaging
Monoclonal antibodies raised against Rudhira were used for the
study [16]. As mouse Rudhira and human BCAS3 proteins are
98% identical, the anti-Rudhira antibody could be used for
detecting the human protein. Antibody specificity was tested by
blocking with immunogen (see Figure S1 of Text S1). Antibody
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Vimentin, anti-Flk-1, anti-PECAM and anti-ICAM2 from BD
Pharmingen, GFAP (Glial fibrillar acidic protein) from Sigma
Chemical Co., USA and SSEA4 from Chemicon (all at 1:50
dilution). Alexa Fluor-conjugated secondary antibodies (Molecular
Probes, USA) were used at a dilution of 1:400 to immuno-localize
the binding of the primary antibody.
Frozen sections of various brain lesions were thawed to room
temperature, washed in PBS, permeabilized with 0.3% Triton X
100 and blocked for non-specific binding sites in 3% skimmed milk
powder in PBS for 1 hr. Sections were incubated in monoclonal
antibody (1:10) overnight in a humid chamber. After washing off
the primary antibody, the immuno-labeling of BCAS3 protein was
visualized by incubating with fluorescent- labeled secondary
antibody (Rabbit anti-Mouse IgG tagged to Alexa Fluor 488
1:400) for 1 hr at RT. Sections were mounted in glycerol
containing DAPI, to stain the nucleus. Adjacent sections (10 mm)
were stained with hematoxylin and eosin. The fluorescent
immunostained sections were viewed under a Carl-Zeiss LSM
510 Meta confocal microscope and the image analysis and
processing was carried out with LSM 5 Image Browser software.
Quantitation was done using MicroImage software (Roper
Scientific, USA) and percentage of BCAS3-expressing (green) cells
out of total number of cells (DAPI stained nuclei) in a sampled
area was estimated. At least 500 cells were analyzed for each
sample. Cultured cells were imaged using an Olympus IX70
fluorescence microscope and CoolSNAP-PROcf camera.
Flow cytometry analysis
Cultured cells were washed twice with PBS, trypsinized to get
single cell suspension and transferred to FACS tubes. Trypsin was
inactivated with 5% fetal calf serum, cells were fixed and
permeabilized simultaneously with cold methanol for 1 min then
washed with PBS. Non-specific binding of antibody was blocked
with staining media (3% serum in PBS) for 45 min at room
temperature. Staining media was then replaced with primary
antibody, incubated at 4uC overnight and unbound antibody was
removed with wash solution (2% serum in PBS). Cells were then
incubated with fluorescent-tagged secondary antibody (Alexa
Fluor 488 goat anti-mouse IgG, at 1:400 dilution in staining
media), washed and finally resuspended in 0.5 ml of PBS and run
through a flow cytometer (Becton Dickinson FACS Calibur
TM
system). The data was analyzed using BD CellQuest Pro software.
SUPPORTING INFORMATION
Figure S1 Immunostaining is abolished by pre-incubation of
antibody with the immunogen. (A,C,E,G) Phase contrast and
(B,D,F,H) fluorescent (red) images of HEK293 cells stained with
antibody preincubated with (A,B) 0 microgram (C,D) 20 microgram
(E,F) 40 microgram and (G,H) 80 microgram of immunogen.
Found at: doi:10.1371/journal.pone.0001202.s001 (4.96 MB TIF)
Text S1 Blocking of antibody binding 50 microliters of undiluted
monoclonal anti-Rudhira/BCAS3 antibody was pre-incubated
with 0, 10, 20, 40 and 80 microgram of the immunogen and at 4
oC for 12 hours, centrifuged to remove any antigen-antibody
complex, diluted 1:10 and used to stain HEK293 cells.
Found at: doi:10.1371/journal.pone.0001202.s002 (0.02 MB
DOC)
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